Investor Kit

Investor Kit

Assemble your own Investor Kit by selecting and printing from the following documents.

Corporate Presentation

DateTitle
11/12/18
Corporate Presentation

Recent SEC Filings

<< First | Previous | Next | Last >>
Filing DateFormDescriptionFiling GroupDownloads
11/13/184Statement of changes in beneficial ownership of securities3,4,5 Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
11/09/184Statement of changes in beneficial ownership of securities3,4,5 Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
11/06/184Statement of changes in beneficial ownership of securities3,4,5 Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
11/01/1810-QQuarterly report which provides a continuing view of a company's financial positionQuarterly Filings Download SEC Filing to Word Download SEC Filing to Excel Download SEC Filing to Adobe PDF Download XBRL Content
11/01/188-KReport of unscheduled material events or corporate eventCurrent Reports Download SEC Filing to Word Download SEC Filing to Excel Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
<< First | Previous | Next | Last >>

Fact Sheets

There are currently no items available.

Recent Press Releases

DateTitle 
12/12/18New Retrospective Analysis Demonstrates Significant Reductions in Postsurgical Pain and Opioid Requirements with EXPAREL in Cesarean Section Patients
Results show incorporating transversus abdominis plane block with EXPAREL results in significantly improved patient functional recovery and hospital throughput Twelve percent of patients receiving EXPAREL were opioid-free PARSIPPANY, N.J., Dec. 12, 2018 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced the publication of new data from a retrospective investigator-initiated study analyzing the use of EXPAREL® (bupivacaine liposome injectable suspension) adminis... 
Printer Friendly Version
12/07/18Pacira Pharmaceuticals to Present at the 2018 BMO Capital Markets Prescriptions for Success Healthcare Conference
PARSIPPANY, N.J., Dec. 07, 2018 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today reported that it will present at the 2018 BMO Capital Markets Prescriptions for Success Healthcare Conference at 1:20 PM ET on Wednesday, December 12, 2018. Live audio of the presentation can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event. About Pacira                ... 
Printer Friendly Version
11/27/18New Data Show EXPAREL Plays a Key Role in Achieving Significant Reductions in Opioid Use, Hospital Stay and Total Hospitalization Costs Following Painful Knee Replacement Surgery
Results show improved clinical and economic outcomes across 10 U.S. hospitals with highest EXPAREL utilization for total knee arthroplasties PARSIPPANY, N.J., Nov. 27, 2018 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced new data on the use of EXPAREL® (bupivacaine liposome injectable suspension) to manage postsurgical pain following total knee arthroplasty (TKA). The findings show that patients receiving EXPAREL had a significant reduction in opioid use, hospi... 
Printer Friendly Version
11/16/18Pacira Pharmaceuticals CMO Presents at FDA Advisory Committee Meeting Focused on Assessment of Opioid-Sparing Outcomes in Clinical Trials
PARSIPPANY, N.J., Nov. 16, 2018 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that Chief Medical Officer Richard Scranton, M.D., M.P.H., was one of three industry representatives invited to provide insight and perspective during the U.S. Food and Drug Administration’s (FDA’s) Anesthetic and Analgesic Drug Products Advisory Committee meeting held yesterday, November 15th. The discussion centered on clinical trial design requirements and endpoints needed to demo... 
Printer Friendly Version
11/08/18Pacira Pharmaceuticals to Present at Healthcare Conferences in November
PARSIPPANY, N.J., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that members of its management team are scheduled to present at the following healthcare conferences: Jefferies 2018 Healthcare Conference in London, on Wednesday, November 14, 2018 at 2:40 PM GMT (9:40 AM ET) Piper Jaffray 30th Annual Healthcare Conference in New York, on Tuesday, November 27, 2018 at 12:30 PM ET A live audio webcast of the Pacira presentations can be a... 
Printer Friendly Version
11/02/18Centers for Medicare and Medicaid Services Establish New Reimbursement for Non-Opioid Options, Including EXPAREL
– Product-specific C-code for ambulatory surgical center procedures to take effect January 1, 2019 – – American Dental Association has established a procedure code for infiltration of a sustained-release therapeutic drug—single or multiple sites to take effect January 1, 2019 – – Important reimbursement milestone that will expand patient access to non-opioid strategies for postsurgical pain – PARSIPPANY, NJ, Nov 2, 2018 – Pacira... 
Printer Friendly Version
11/01/18Pacira Pharmaceuticals, Inc. Reports Third Quarter 2018 Financial Results
-- EXPAREL® net product sales of $82.2 million up 23% over prior year third quarter -- -- Full-year EXPAREL net product sales guidance increased to $325 to $330 million -- -- Conference Call Today at 8:30 a.m. ET -- PARSIPPANY, N.J., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced consolidated financial results for the third quarter ended September 30, 2018. “As evident from these financial results, EXPAREL continues to deliver impressive sales... 
Printer Friendly Version
10/30/18Aetna Offers Expanded Coverage for EXPAREL® in Select Ambulatory Surgical Centers 
Aetna will reimburse for the use of EXPAREL in ambulatory surgical centers in Florida and New Jersey as part of a pilot program       PARSIPPANY, N.J., Oct. 30, 2018 (GLOBE NEWSWIRE) -- Aetna has announced that they will reimburse select ambulatory surgical centers (ASCs) for the use of EXPAREL® (bupivacaine liposome injectable suspension) as part of a pilot program in Florida and New Jersey. The purpose of the program is to incentivize the use of non-opioid therapies for postsurgical pain ma... 
Printer Friendly Version
10/25/18Pacira to Report Third Quarter 2018 Financial Results on Thursday November 1, 2018
PARSIPPANY, N.J., Oct. 25, 2018 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that it will report its third quarter financial results before the open of the U.S. markets on Thursday, November 1, 2018. Following the release, the company will host a live conference call and webcast at 8:30 a.m. ET. To participate in the conference call, dial 1-877-845-0779 and provide the passcode 1988603. International callers may dial 1-720-545-0035 and use the same passcode... 
Printer Friendly Version
10/11/18New Research Reveals Potency and Quantity of Opioids Prescribed for Postsurgical Pain Poses Danger to Patients, their Families and Friends
Patients prescribed nearly 100 to 200 opioid pills to help manage pain from four common procedures Persistent opioid use spikes among millennial women; Nearly one-in-five millennials report becoming addicted to or dependent on opioids following surgery   PARSIPPANY, N.J., Oct. 11, 2018 (GLOBE NEWSWIRE) -- Despite ongoing efforts to end America’s opioid crisis, patients continue to receive large quantities of opioids for postsurgical pain. New research shows that patients received nearly 1... 
Printer Friendly Version
>> Access Older Press Releases